|
Direct-Haler A/S is a privately owned drug delivery company. We focus on research & development and out-licensing of innovative and world-wide patented drug delivery device technology for pulmonary and nasal delivery.
In the array of new drug delivery routes, the pulmonary and nasal delivery routes offer many advantages, which are waiting to be exploited for a range of drug classes and therapy areas.
Patented technologies
Direct-Haler A/S is with background in own R&D, offering effective, easy-to-use, innovative and world-wide patented drug delivery devices for pulmonary and nasal delivery of dry powder formulations:
Licensees
Zambon Group SpA has acquired exclusive world-wide license for DirectHaler™ Pulmonary in one therapy area: Respiratory diseases (asthma, COPD etc).
Our technologies meet unmet needs
The philosophy applied in the R&D of the DirectHaler™ devices, has been to broaden the development scope not only to focus on the unmet needs of the patient. The DirectHaler™ drug delivery devices meet unmet needs of patients, GPs, instruction nurses, pharmacies, sales representatives.
Our device technologies are developed to enable pharmaceutical – and biotechnology companies to obtain maximum flexibility in supply of device parts: If wanted, then our licensees can acquire right to establish own manufacturing, filling and packing of DirectHaler™ devices.
Partnering outlook
Direct-Haler A/S has a flexible outlook on the development of the companys business, and in how our technologies can become fully commercialized.
We are seeking partnerships both concerning out-licensing of the DirectHaler™ technologies, and for accessing complementary technology to our device technologies.
|
